Bal Pharma Ltd's earnings have grown by 33.5%, whereas share price has declined -3.7% CAGR over the past five years, indicating the company’s share price is likely undervalued. However, for specific investment actions please consult your investment advisor.
Bal Pharma Ltd share price has appreciated 16.6% annually (CAGR) over the past ten years.
Data is not available for this company.
Bal Pharma, incorporated in 1987 is engaged in the business interest in area of manufacturing API, finished formulations, ayurvedic and research and development. It is one of the leading Indian pharmaceutical companies that focuses on prescription drugs, generic, OTC products, intravenous infusion and bulk actives.
The company exports APIs to countries like Japan, Australia,
The company exports APIs to countries like Japan, Australia, Spain, UK, Canada, Nigeria, Iceland, Slovenia, Romania, Argentina, Brazil, Pakistan, Germany, South Africa, Serbia, Taiwan, Malaysia, Thailand, Turkey, Egypt, Korea, Venezuela, Italy, Portugal, Morocco, Poland, Netherlands, Syria, Bangladesh, and Indonesia, etc.
It offers products for treatment for diabetes, cardiometabolics, gynaecology, dermatology, gastroenterology, orthopaedics, ENT and multi-speciality segments.
In India, the company operates its marketing through 5 divisions namely Multi-Specialty, Glyduz, Servetus, Bal Vedics and Zennova. It has distribution network of 1000 wholesalers that caters over 1,00,000 retailers.
The company produces range of APIs that includes Anti Histamine, Platelet inhibitor, Antidiabetic, Anti Convulsant, urinary incontinence, Neuropathic pain, Anti allergy, Anti inflammatory, Diuretic, Acne Treatment etc
Bal Pharma's R&D unit is engaged in developing processes for novel bulk actives (active pharmaceutical ingredients, APIs) and new chemical substances for therapeutic applications.
The companyâ€™s manufacturing facilities has been approved by WHO-GMP and has obtained the ISO 9001:2000 accreditations for quality management.
Bal Pharma is planning to set up new facility in Uttaranchal, with an objective to enter into regulated markets. The company also plans to foray in the business of contract manufacturing.